A purple and pink letter v on a white background.
January 13, 2025

What Is a Semaglutide Weight Loss Clinic Model?

Plenty of medical advancements have made addressing obesity and weight-related conditions more manageable for countless patients. Among all the latest weight loss programs available, semaglutide has become a popular option, with many reporting promising results in significant weight reduction. 


While plenty of clinics offer s
emaglutide-based treatments, providing your clients with holistic weight management is essential. Understanding both the advantages and limitations of semaglutide and tirzepatide weight loss clinics can help aesthetic facilities improve their patients’ journey towards healthier body weight. 


Speak to an expert today to learn how Venus' technologies and expertise can help you deliver comprehensive weight management solutions to your clients.


What Are Semaglutide Weight Loss Clinics?


Semaglutide weight loss clinics are specialized medical facilities that leverage semaglutide-based treatments to help individuals achieve their weight loss goals. 


Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been clinically proven to cause significant weight loss and is known to suppress appetite and regulate blood sugar levels. This (or tirzepatide, another GLP-1 receptor agonist), along with tailored, medically-supervised plans and lifestyle modifications, can help patients achieve significant weight loss results that are both safe and effective.


How Semaglutide Weight Loss Clinics Work


The weight loss clinic semaglutide program model is structured around personalized patient care, providing a thorough approach to weight management. While some service providers can vary, here is a general overview of how these clinics operate:


  1. Initial Consultation and Assessment: Patients schedule an in-depth consultation with a medical professional. After discussing their medical history, current health status, and weight loss goals, comprehensive lab tests may be conducted to ensure they are suitable for semaglutide treatments.

  2. Customized Treatment Plan: If a patient is qualified, they are given a tailored plan that includes the dosage of semaglutide, dietary guidelines, and an exercise regimen. Clinics often integrate behavioral counseling to address the psychological aspects of weight loss.

  3. Medication Administration and Monitoring: Semaglutide is typically administered via subcutaneous injections. Patients are trained on self-administration, and regular follow-ups are scheduled to monitor progress, adjust dosages, and address any side effects.

  4. Lifestyle and Nutritional Support: Most clinics emphasize the importance of a balanced diet and physical activity. Nutritionists and fitness experts may be part of the team to provide ongoing support.

  5. Long-Term Maintenance: After achieving the desired weight loss, clinics guide patients on maintaining their results. This often includes continued medication at a maintenance dose and sustained lifestyle practices.


Who Can Benefit From Semaglutide Weight Loss Clinic Treatment?


Patients must see a medical professional before undergoing weight loss clinic semaglutide programs. Pregnant women and individuals with contraindications to GLP-1 receptor agonists may not be suitable candidates. Eligible candidates typically include:


  • Patients with Obesity: Individuals with a body mass index (BMI) of 30 or higher are often considered prime candidates for semaglutide treatment.

  • Individuals With Overweight and Co-morbidities: Those with a BMI of 27 or higher and at least one weight-related condition, such as type 2 diabetes, hypertension, or sleep apnea, may benefit from this approach.

  • People Seeking Medically Supervised Weight Loss: These clinics provide a structured and evidence-based alternative for individuals who have tried traditional weight loss methods without success.


Why Semaglutide and Tirzepatide Weight Loss Clinics Might Not Be Enough


Treatments with semaglutide and tirzepatide have made weight management more effective and accessible for countless patients seeking healthy weight loss. However, some weight loss programs may not address all aspects of a patient's weight loss journey. Consider these limitations:


  • Plateauing Results: Some patients may experience a plateau in their weight loss progress, requiring additional interventions to achieve their goals.

  • Skin Elasticity: Rapid weight loss can lead to loose skin, a common concern for many not addressed by medication alone. This is best addressed with skin tightening treatments to combat post-weight loss sagging skin.

  • Localized Fat Reduction: Semaglutide promotes overall weight loss but may not specifically target stubborn fat deposits in areas like the abdomen, thighs, or arms. Body treatments, like non-invasive fat reduction, can address patients’ problem areas by helping shrink stubborn fat cells.

  • Decreased Muscle Tone: Significant weight loss may reduce muscle tone, impacting physical aesthetics and functionality. Electrical muscle stimulation (EMS) treatments target muscle groups to create a more defined muscle appearance.

  • Patient Satisfaction: A holistic approach combining medical treatment with aesthetic treatments can significantly improve patient satisfaction by addressing functional and cosmetic concerns.


How Can Venus Bliss MAX™ Round Out Your Weight Loss Programs?


Venus Bliss MAX™ is an innovative aesthetic device designed to complement semaglutide weight loss treatments by addressing the common concerns post-weight loss – including stubborn fat, loose skin, and muscle tone. By incorporating this technology into your weight loss clinic model, you can provide patients with a more holistic solution that better reaches their ideal weight and appearance. 

Venus Bliss MAX offers these key features:


  • Non-Invasive Fat Reduction: Venus Bliss MAX uses diode laser technology to target and eliminate fat cells in specific areas, helping patients achieve a more contoured appearance.

  • Skin Tightening: Leverage radiofrequency energy to stimulate collagen production, improving skin elasticity and reducing sagging caused by rapid weight loss.

  • Muscle Toning: Venus Bliss MAX includes EMS technology to tone and strengthen muscles, enhancing aesthetic results.


By rounding out your weight loss programs with Venus Bliss MAX, you can position your facility to provide comprehensive weight management and aesthetic care solutions. Provide a holistic approach that delivers on your patients’ goals while also helping you:


  • Enhance Patient Outcomes: Combining semaglutide treatments with Venus Bliss MAX™ ensures that both functional and cosmetic aspects of weight loss are addressed. This can lead to higher patient satisfaction.

  • Increase Revenue Streams: Offering non-surgical aesthetic body treatments alongside medical weight-loss treatments creates opportunities for clinics to expand their service portfolio and attract a broader clientele.

  • Establish Industry Authority: The weight loss and aesthetics industry is constantly evolving due to technological and medical advancements. Leverage the latest technology available to stand out in a highly competitive field. 


Improve Your Weight Loss Clinic Semaglutide Programs With Venus


Semaglutide weight loss clinics offer patients a medically supervised and effective pathway to achieving their weight loss goals. However, as with any treatment model, limitations need to be addressed to ensure holistic patient care. With cutting-edge technologies from Venus, your clinic can overcome these challenges and deliver a superior patient experience.


Elevate your weight loss programs with a more comprehensive approach to weight management. Learn more about Venus Bliss MAX™, or get in touch with Venus for more information about our innovative solutions.



September 9, 2026
TORONTO, September 9 th , 2026 (GLOBE NEWSWIRE) – Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition. The Board believes that Brad’s commercial leadership experience, strategic vision, and industry expertise position the Company well for its next phase of growth and value creation. Brad brings more than 20 years of leadership experience in the aesthetic industry, most recently as President & General Manager – Americas at Lumenis, and has a proven track record of driving growth globally, operational excellence, and innovation. "I am honored to be appointed Chief Executive Officer of Venus Concept and grateful for the confidence the Board has placed in me,” said Mr. Oliver. “The Company has established a strong foundation under Rajiv's leadership, and I look forward to working closely with him during the transition. Together with our employees, customers, and partners, we will remain focused on disciplined commercial execution, product innovation, profitable growth, and creating long-term value for our customers, employees, and shareholders.” “It has been a pleasure to lead Venus through a transformational time in the organization’s journey,” said Mr. De Silva. “I am grateful for the opportunity to work together with the leadership team, the Board and our partners to grow the business. We have transformed the commercial, operational and financial capabilities of the organization and built a strong foundation for the future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. I look forward to supporting a smooth transition and watching Venus continue its transformation under Brad’s new leadership.” The Board expresses its gratitude to Rajiv for his leadership and ongoing commitment to the Company. As Special Advisor, Rajiv will work closely with Brad during the transition period to ensure continuity across strategic, operational, and customer-facing initiatives. “On behalf of the Board, I would like to thank Rajiv for his leadership and contributions to the Company and for his support during this transition to ensure a seamless handoff of leadership responsibilities,” said Avinash Amin, M.D., Managing Partner of Madryn Asset Management and Chairman of the Board. “The Board looks forward to Brad’s new leadership of the organization and is confident that his expertise will accelerate commercial efforts globally and the execution of its strategic priorities as the company progresses towards continuing to establish a leadership position in the Medical Device Aesthetics industry.” The leadership transition is not expected to impact the Company’s strategic priorities, customer relationships, employee commitments, or ongoing business operations. Venus Concept remains focused on delivering innovative solutions to its customers, expanding market opportunities, and driving sustainable long-term growth. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft ® and the ARTAS iX ® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. View Full Article Investor Relations Contact : Damian Yeung, CPA investorrelations@venus.ai
Purple gradient branding graphic for Doublo × Venus Signature Edition
July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.